礼来：小分子Lpa启动三期临床

药渡

09/08

▎Armstrong2025年9月5日，礼来在Clinicaltrials.gov网站上注册了小分子Lpa抑制剂Muvalaplin用于降低伴Lp(a)水平升高患者MACE发生风险的三期临床试验。该三期临床试验计划入组10450例Lpa升高的受试者，预计2031年完成。礼来于2024年11月在JAMA期刊上发表了Muvalaplin的二期临床数据。Muvalaplin治疗12周时，相比于安慰剂，...

网页链接

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2565732075"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2565732075\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2565732075?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":false,"pubTime":"2025-09-08 07:32","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2565732075","market":"us","top_or_hot":-1,"title":"礼来：小分子Lpa启动三期临床","media":"药渡","content":"<div>\n<p>▎Armstrong2025年9月5日，礼来在Clinicaltrials.gov网站上注册了小分子Lpa抑制剂Muvalaplin用于降低伴Lp(a)水平升高患者MACE发生风险的三期临床试验。该三期临床试验计划入组10450例Lpa升高的受试者，预计2031年完成。礼来于2024年11月在JAMA期刊上发表了Muvalaplin的二期临床数据。Muvalaplin治疗12周时，相比于安慰剂，...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250908074317a7151dda&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>礼来：小分子Lpa启动三期临床</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n礼来：小分子Lpa启动三期临床\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-09-08 07:32 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250908074317a7151dda&s=b><strong>药渡</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>▎Armstrong2025年9月5日，礼来在Clinicaltrials.gov网站上注册了小分子Lpa抑制剂Muvalaplin用于降低伴Lp(a)水平升高患者MACE发生风险的三期临床试验。该三期临床试验计划入组10450例Lpa升高的受试者，预计2031年完成。礼来于2024年11月在JAMA期刊上发表了Muvalaplin的二期临床数据。Muvalaplin治疗12周时，相比于安慰剂，...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250908074317a7151dda&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0640476718.USD","symbol_name":"THREADNEEDLE (LUX) US CONTRARIAN CORE EQ \"AU\" (USD) ACC","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250908074317a7151dda&s=b","article_id":"2565732075","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250908074317a7151dda&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2565732075","pubTimestamp":1757287944,"columns":[],"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"▎Armstrong2025年9月5日，礼来在Clinicaltrials.gov网站上注册了小分子Lpa抑制剂Muvalaplin用于降低伴Lp水平升高患者MACE发生风险的三期临床试验。该三期临床试验计划入组10450例Lpa升高的受试者，预计2031年完成。礼来围绕Lpa进行了深度布局，Lpa siRNA新药Lepodisiran于去年启动三期临床，今年5月其二期临床数据发表在新英格兰医学期刊上。安进、诺华布局了小核酸药物，礼来同时布局小核酸与siRNA药物，默沙东引进了恒瑞医药的小分子Lpa抑制剂，阿斯利康引进了石药集团的小分子Lpa抑制剂。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"LU0640476718.USD":"THREADNEEDLE (LUX) US CONTRARIAN CORE EQ \"AU\" (USD) ACC","LU2211815571.USD":"ALLIANZ POSITIVE CHANGE \"AT\" (USD) ACC","LU0320765992.SGD":"FTIF - Franklin Biotechnology Discovery A Acc SGD","LU0689472784.USD":"安联收益及增长基金Cl AM AT Acc","BK4533":"AQR资本管理(全球第二大对冲基金)","SGXZ51526630.SGD":"大华环球创新基金A Acc SGD","LU0096364046.USD":"CT (LUX) I AMERICAN \"DU\" (USD) ACC","LU0238689110.USD":"贝莱德环球动力股票基金","LU0823416689.USD":"BNP PARIBAS HEALTH CARE INNOVATORS \"C\" (USD) ACC","LU2471134952.CNY":"INVESCO GLOBAL EQUITY INCOME ADVANTAGE \"A\" (CNYHDG) INC","BK4516":"特朗普概念","LU1064131342.USD":"Fullerton Lux Funds - Global Absolute Alpha A Acc USD","LU0823434583.USD":"BNP PARIBAS US GROWTH \"C\" (USD) ACC","BK4534":"瑞士信贷持仓","LU1988902786.USD":"FULLERTON LUX FUNDS GLOBAL ABSOLUTE ALPHA \"I\" (USD) ACC","LU2087625088.SGD":"ALLSPRING  US ALL CAP GROWTH \"A\" (SGDHDG) ACC","LU0354030438.USD":"富国美国大盘成长基金Cl A Acc","LLY":"礼来","LU0122379950.USD":"贝莱德世界健康科学A2","LU2237443549.SGD":"Aberdeen Standard SICAV I - Global Dynamic Dividend A MIncA SGD-H","LU0289739699.SGD":"AB INTERNATIONAL HEALTH CARE PORTFOLIO \"A\" (SGD) ACC","LU1551013425.SGD":"Allianz Income and Growth Cl AMg2 DIS H2-SGD","LU0006306889.USD":"SCHRODER ISF US LARGE CAP \"A\" (USD) INC AV","LU2236285917.USD":"ALLIANZ GLOBAL INCOME \"AMG\" (USD) INC","IE00B2B36J28.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I1\" (USD) INC","LU0109394709.USD":"富兰克林生物科技新领域基金A (acc)","SGXZ81514606.USD":"大华环球创新基金A Acc USD","LU0320765059.SGD":"FTIF - Franklin US Opportunities A Acc SGD","IE00BJT1NW94.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (SGDHDG) ACC","LU1814569148.SGD":"WELLINGTON GLOBAL QUALITY GROWTH \"D\" (SGDHDG) ACC","LU1093756325.SGD":"FTIF - Franklin K2 Alt Strat Fd A (acc) SGD-H1","LU2491049909.HKD":"WELLINGTON SUSTAINABLE OUTCOMES \"A\" (HKD) ACC","LU1720051017.SGD":"Allianz Global Artificial Intelligence AT Acc H2-SGD","LU2265009873.SGD":"Eastspring Investments - Global Growth Equity AS SGD-H","LU1267930730.SGD":"富兰克林美国机遇基金AS Acc SGD (CPF)","LU2357305700.SGD":"Allianz Global Artificial Intelligence ET H2-SGD","SG9999015952.SGD":"LIONGLOBAL DISRUPTIVE INNOVATION \"I\" (SGD) ACC","LU0708995401.HKD":"FRANKLIN U.S. OPPORTUNITIES \"A\" (HKD) ACC","SG9999014906.USD":"大华全球优质成长基金Acc USD","LU0820561818.USD":"安联收益及增长平衡基金Cl AM DIS","LU0417517546.SGD":"Allianz US Equity Cl AT Acc SGD","LU2491050154.USD":"WELLINGTON SUSTAINABLE OUTCOMES \"A\" (USD) ACC","BK4599":"减肥药","LU1868836591.USD":"CT (LUX) I AMERICAN \"1U\"(USD) ACC","IE00BJJMRZ35.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (SGDHDG) ACC","IE00BFTCPJ56.SGD":"Janus Henderson Global Life Sciences A Acc SGD","LU0882574139.USD":"富达环球消费行业基金A ACC","LU2471134796.USD":"INVESCO GLOBAL EQUITY INCOME ADVANTAGE \"A\" (USD) INC","LU0256863811.USD":"ALLIANZ US EQUITY \"A\" INC","LU1720051108.HKD":"ALLIANZ GLOBAL ARTIFICIAL INTELLIGENCE \"AT\" (HKD) ACC"},"translate_title":"Eli Lilly: Small molecule Lpa starts phase III clinical trial","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"LLY":1},"content_text":"▎Armstrong2025年9月5日，礼来在Clinicaltrials.gov网站上注册了小分子Lpa抑制剂Muvalaplin用于降低伴Lp(a)水平升高患者MACE发生风险的三期临床试验。该三期临床试验计划入组10450例Lpa升高的受试者，预计2031年完成。礼来于2024年11月在JAMA期刊上发表了Muvalaplin的二期临床数据。Muvalaplin治疗12周时，相比于安慰剂，muvalaplin 10 mg、60 mg组、240 mg剂量组的Lpa相对基线降幅分别为47.6%、81.7%、85.8%。礼来围绕Lpa进行了深度布局，Lpa siRNA新药Lepodisiran于去年启动三期临床，今年5月其二期临床数据发表在新英格兰医学期刊上。Lepodisiran 400mg剂量组半年给药一针，可以将Lpa降低93.9%，抑制幅度显著超过小分子。总结作为慢病药物，小分子和小核酸都有其应用场景，siRNA可以3个月乃至6个月给药一针，小分子则可以通过口服给药。安进、诺华布局了小核酸药物，礼来同时布局小核酸与siRNA药物，默沙东引进了恒瑞医药的小分子Lpa抑制剂，阿斯利康引进了石药集团的小分子Lpa抑制剂。药渡媒体商务合作媒体公关 | 新闻&会议发稿张经理：18600036371（微信同号）点击下方“药渡“，关注更多精彩内容","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}